Patents by Inventor Julia JUNG

Julia JUNG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12337068
    Abstract: Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.
    Type: Grant
    Filed: September 16, 2024
    Date of Patent: June 24, 2025
    Assignee: ReCode Therapeutics, Inc.
    Inventors: Mirko Hennig, Ali Ahmed Alfaifi, Sakya Sing Mohapatra, Daniella Ishimaru, Vladimir Grigor'evich Kharitonov, Julia Jung-un Baek, Shuang Li, David J. Lockhart, Brandon A. Wustman, Yufeng Wang, Joseph S. Cefalu
  • Publication number: 20250188440
    Abstract: Provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.
    Type: Application
    Filed: February 5, 2024
    Publication date: June 12, 2025
    Inventors: Mirko Hennig, Sakya Sing Mohapatra, Daniella Ishimaru, Joseph S. Cefalu, Ali Ahmed Alfaifi, Julia Jung-un Baek, Hu Meng, Jeremy Monroe
  • Publication number: 20250032424
    Abstract: Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.
    Type: Application
    Filed: September 16, 2024
    Publication date: January 30, 2025
    Inventors: Mirko Hennig, Ali Ahmed Alfaifi, Sakya Sing Mohapatra, Daniella Ishimaru, Vladimir Grigor'evich Kharitonov, Julia Jung-un Baek, Shuang Li, David J. Lockhart, Brandon A. Wustman, Yufeng Wang, Joseph S. Cefalu
  • Patent number: 12133923
    Abstract: Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.
    Type: Grant
    Filed: January 16, 2024
    Date of Patent: November 5, 2024
    Assignee: ReCode Therapeutics, Inc.
    Inventors: Mirko Hennig, Ali Ahmed Alfaifi, Sakya Sing Mohapatra, Daniella Ishimaru, Vladimir Grigor'evich Kharitonov, Julia Jung-un Baek, Shuang Li, David J. Lockhart, Brandon A. Wustman, Yufeng Wang, Joseph S. Cefalu
  • Publication number: 20240285533
    Abstract: Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for cystic fibrosis (CF), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject, wherein the LNPs comprise mRNA encoding a Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein.
    Type: Application
    Filed: March 1, 2024
    Publication date: August 29, 2024
    Inventors: Mirko Hennig, Ali Ahmed Alfaifi, Sakya Sing Mohapatra, Daniella Ishimaru, Vladimir Grigor'evich Kharitonov, Julia Jung-un Baek, Shuang Li, David J. Lockhart, Brandon A. Wustman, Yufeng Wang, Joseph S. Cefalu
  • Patent number: 11661582
    Abstract: The electrical pacemakers currently being used for the therapeutic approaches for treatment of “sick sinus syndrome” are not hormonally regulatable and entail risks through infections or premature battery discharge. These problems could be overcome by means of “biological cardiac pacemakers” obtained from pluripotent stem cells (PSCs). It has been shown that the controlled differentiation of stem cells with TBX, inductors of sinoatrial node cells, and an additional Myh6 promoter-specific antibiotic selection can give cardiomyocyte aggregates consisting to an extent of more than 80% of physiologically functional pacemaker cells. These induced sinoatrial bodies (“iSABs”) for the first time exhibited very high beat frequencies (300-400 bpm), similar to those in a murine heart, and were able to stably rhythmically stimulate heart muscle cells ex vivo.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: May 30, 2023
    Assignee: UNIVERSITAET ROSTOCK
    Inventors: Robert David, Julia Jung
  • Publication number: 20210290956
    Abstract: The present invention relates to a bioelectronic system comprising at least i) in vitro generated cardiac pacemaker tissue comprising cardiac pacemaker cells; ii) an electronic circuit applied to a semiconductor carrier and comprising at least one field-effect transistor; wherein the in vitro generated cardiac pacemaker tissue comprising cardiac pacemaker cells according to i) is immobilized on the electronic circuit according to ii) applied to the semiconductor carrier and is arranged in conductive communication with the at least one field-effect transistor.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 23, 2021
    Inventors: Robert David, Christian Rimmbach, Julia Jung
  • Publication number: 20170107494
    Abstract: The electrical pacemakers currently being used for the therapeutic approaches for treatment of “sick sinus syndrome” are not hormonally regulatable and entail risks through infections or premature battery discharge. These problems could be overcome by means of “biological cardiac pacemakers” obtained from pluripotent stem cells (PSCs). It has been shown that the controlled differentiation of stem cells with TBX, inductors of sinoatrial node cells, and an additional Myh6 promoter-specific antibiotic selection can give cardiomyocyte aggregates consisting to an extent of more than 80% of physiologically functional pacemaker cells. These induced sinoatrial bodies (“iSABs”) for the first time exhibited very high beat frequencies (300-400 bpm), similar to those in a murine heart, and were able to stably rhythmically stimulate heart muscle cells ex vivo.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 20, 2017
    Inventors: Robert DAVID, Julia JUNG